keyword
MENU ▼
Read by QxMD icon Read
search

Major Depressive Disorder SLC6A4

keyword
https://www.readbyqxmd.com/read/28645747/a-review-of-dna-methylation-in-depression
#1
REVIEW
Dongmei Chen, Lin Meng, Fei Pei, Yang Zheng, Jiyan Leng
As one of the most common psychiatric disorders, depression has been a major public health problem. Growing evidence suggests that epigenetic modification is essential in biological processes of depression. Recently, DNA methylation has been regarded as a potential link between environment and depression. In this review, we reviewed current studies of the association between DNA methylation and depression. The association between DNA methylation of seven genes, including BDNF, SLC6A4, NR3C1, 5-HTR (1A, 2A, and 3A), FKBP5, MAO-A and OXTR, and depression were reviewed in this study...
June 20, 2017: Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia
https://www.readbyqxmd.com/read/28515818/pharmacogenomic-testing-for-psychotropic-medication-selection-a-systematic-review-of-the-assurex-genesight-psychotropic-test
#2
(no author information available yet)
BACKGROUND: A large proportion of the Ontario population lives with a diagnosed mental illness. Nearly 5% of Ontarians have major depressive disorder, and another 5% have another type of depressive disorder, bipolar disorder, schizophrenia, anxiety, or some other disorder not otherwise specified. Medications are commonly used to treat mental illness, but choosing the right medication for each patient is challenging, and more than 40% of patients discontinue their medication within 90 days because of adverse effects or lack of response...
2017: Ontario Health Technology Assessment Series
https://www.readbyqxmd.com/read/28456840/rapid-evidence-review-of-the-comparative-effectiveness-harms-and-cost-effectiveness-of-pharmacogenomics-guided-antidepressant-treatment-versus-usual-care-for-major-depressive-disorder
#3
REVIEW
Kimberly Peterson, Eric Dieperink, Johanna Anderson, Erin Boundy, Lauren Ferguson, Mark Helfand
OBJECTIVE: This study aims to conduct an evidence review of the effectiveness, harms, and cost-effectiveness of pharmacogenomics-guided antidepressant treatment for major depressive disorder. METHODS: We searched MEDLINE®, the Cochrane Central Registry of Controlled Trials, and PsycINFO through February 2017. We used prespecified criteria to select studies, abstract data, and rate internal validity and strength of the evidence (PROSPERO number CRD42016036358). RESULTS: We included two randomized trials (RCT), five controlled cohort studies, and six modeling studies of mostly women in their mid-40s with few comorbidities...
June 2017: Psychopharmacology
https://www.readbyqxmd.com/read/28260899/gene-expression-based-biological-test-for-major-depressive-disorder-an-advanced-study
#4
Shin-Ya Watanabe, Shusuke Numata, Jun-Ichi Iga, Makoto Kinoshita, Hidehiro Umehara, Kazuo Ishii, Tetsuro Ohmori
PURPOSE: Recently, we could distinguished patients with major depressive disorder (MDD) from nonpsychiatric controls with high accuracy using a panel of five gene expression markers (ARHGAP24, HDAC5, PDGFC, PRNP, and SLC6A4) in leukocyte. In the present study, we examined whether this biological test is able to discriminate patients with MDD from those without MDD, including those with schizophrenia and bipolar disorder. PATIENTS AND METHODS: We measured messenger ribonucleic acid expression levels of the aforementioned five genes in peripheral leukocytes in 17 patients with schizophrenia and 36 patients with bipolar disorder using quantitative real-time polymerase chain reaction (PCR), and we combined these expression data with our previous expression data of 25 patients with MDD and 25 controls...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/28068779/norepinephrine-transporter-gene-variants-and-remission-from-depression-with-venlafaxine-treatment-in-older-adults
#5
MULTICENTER STUDY
Victoria S Marshe, Malgorzata Maciukiewicz, Soham Rej, Arun K Tiwari, Etienne Sibille, Daniel M Blumberger, Jordan F Karp, Eric J Lenze, Charles F Reynolds, James L Kennedy, Benoit H Mulsant, Daniel J Müller
OBJECTIVE: The primary objective of this study was to investigate five putatively functional variants of the norepinephrine transporter (SLC6A2, NET) and serotonin transporter (SLC6A4, SERT) genes and remission in depressed older adults treated with venlafaxine. A secondary objective was to analyze 17 other variants in serotonergic system genes (HTR1A, HTR2A, HTR1B, HTR2C, TPH1, TPH2) potentially involved in the mechanism of action of venlafaxine. METHOD: The sample included 350 adults age 60 or older with DSM-IV-defined major depressive disorder and a score of at least 15 on the Montgomery-Åsberg Depression Rating Scale (MADRS)...
May 1, 2017: American Journal of Psychiatry
https://www.readbyqxmd.com/read/28063933/dna-methylation-and-clinical-response-to-antidepressant-medication-in-major-depressive-disorder-a-review-and-recommendations
#6
REVIEW
Amanda J Lisoway, Clement C Zai, Arun K Tiwari, James L Kennedy
Antidepressant medications are the most common treatment for major depression and related disorders. Pharmacogenetic studies have demonstrated that response to these medications is associated with genetic variation. While these studies have been invaluable they have yet to explain why a significant number of patients do not respond to their initial medication. The epigenetic modification known as DNA methylation has recently been studied in the context of antidepressant treatment response. As such, the purpose of this article is to review the advances made in the relatively new field of pharmaco-epigenetics of antidepressant response...
January 4, 2017: Neuroscience Letters
https://www.readbyqxmd.com/read/27998510/stress-burnout-and-depression-a-systematic-review-on-dna-methylation-mechanisms
#7
REVIEW
Jelena Bakusic, Wilmar Schaufeli, Stephan Claes, Lode Godderis
Despite that burnout presents a serious burden for modern society, there are no diagnostic criteria. Additional difficulty is the differential diagnosis with depression. Consequently, there is a need to dispose of a burnout biomarker. Epigenetic studies suggest that DNA methylation is a possible mediator linking individual response to stress and psychopathology and could be considered as a potential biomarker of stress-related mental disorders. Thus, the aim of this review is to provide an overview of DNA methylation mechanisms in stress, burnout and depression...
January 2017: Journal of Psychosomatic Research
https://www.readbyqxmd.com/read/27964944/resequencing-three-candidate-genes-discovers-seven-potentially-deleterious-variants-susceptibility-to-major-depressive-disorder-and-suicide-attempts-in-chinese
#8
Shitao Rao, Cherry She Ting Leung, Macro Hb Lam, Yun Kwok Wing, Mary Miu Yee Waye, Stephen Kwok Wing Tsui
BACKGROUND: To date almost 200 genes were found to be associated with major depressive disorder (MDD) or suicide attempts (SA), but very few genes were reported for their molecular mechanisms. This study aimed to find out whether there were common or rare variants in three candidate genes altering the risk for MDD and SA in Chinese. METHODS: Three candidate genes (HOMER1, SLC6A4 and TEF) were chosen for resequencing analysis and association studies as they were reported to be involved in the etiology of MDD and SA...
March 1, 2017: Gene
https://www.readbyqxmd.com/read/27889704/pharmacogenetic-studies-a-tool-to-improve-antidepressant-therapy
#9
Marta Ramos, Cecilia Berrogain, Julia Concha, Laura Lomba, Cristina Belén García, Mª Pilar Ribate
The World Health Organization (WHO) predicts that major depressive disorder (MDD) will be the second leading cause of death and disability by 2020. Nowadays, approximately 60-70% of patients with this disorder have shown the lack of effectiveness and tolerability of the therapy with antidepressants. The US Food and Drug Administration (FDA) and the European Medicine Agency (EMA) are including pharmacogenetic information in the labeling of several antidepressants. The presence of this information represents the relevance of genetic polymorphisms in drug response...
December 1, 2016: Drug Metabolism and Personalized Therapy
https://www.readbyqxmd.com/read/27763986/prenatal-major-depressive-disorder-placenta-glucocorticoid-and-serotonergic-signaling-and-infant-cortisol-response
#10
Laura R Stroud, George D Papandonatos, Stephanie H Parade, Amy L Salisbury, Maureen G Phipps, Barry M Lester, James F Padbury, Carmen J Marsit
OBJECTIVES: Extending prior studies of prenatal adversity and depressive symptoms, we tested associations between maternal prenatal major depressive disorder (MDD) and infant cortisol regulation. Based on prior findings by our group, we also tested placenta glucocorticoid (HSD11B2 methylation) and serotonin (SLC6A4 gene expression) signaling as moderators of links between prenatal MDD and infant cortisol. METHODS: Participants were 153 mother-infant pairs from a low-income, diverse sample (M [SD] age = 26 [6] years)...
November 2016: Psychosomatic Medicine
https://www.readbyqxmd.com/read/27603714/consensus-paper-of-the-wfsbp-task-force-on-genetics-genetics-epigenetics-and-gene-expression-markers-of-major-depressive-disorder-and-antidepressant-response
#11
REVIEW
Chiara Fabbri, Ladislav Hosak, Rainald Mössner, Ina Giegling, Laura Mandelli, Frank Bellivier, Stephan Claes, David A Collier, Alejo Corrales, Lynn E Delisi, Carla Gallo, Michael Gill, James L Kennedy, Marion Leboyer, Amanda Lisoway, Wolfgang Maier, Miguel Marquez, Isabelle Massat, Ole Mors, Pierandrea Muglia, Markus M Nöthen, Michael C O'Donovan, Jorge Ospina-Duque, Peter Propping, Yongyong Shi, David St Clair, Florence Thibaut, Sven Cichon, Julien Mendlewicz, Dan Rujescu, Alessandro Serretti
Major depressive disorder (MDD) is a heritable disease with a heavy personal and socio-economic burden. Antidepressants of different classes are prescribed to treat MDD, but reliable and reproducible markers of efficacy are not available for clinical use. Further complicating treatment, the diagnosis of MDD is not guided by objective criteria, resulting in the risk of under- or overtreatment. A number of markers of MDD and antidepressant response have been investigated at the genetic, epigenetic, gene expression and protein levels...
February 2017: World Journal of Biological Psychiatry
https://www.readbyqxmd.com/read/27505229/association-between-reduced-white-matter-integrity-in-the-corpus-callosum-and-serotonin-transporter-gene-dna-methylation-in-medication-naive-patients-with-major-depressive-disorder
#12
E Won, S Choi, J Kang, A Kim, K-M Han, H S Chang, W S Tae, K R Son, S-H Joe, M-S Lee, B-J Ham
Previous evidence suggests that the serotonin transporter gene (SLC6A4) is associated with the structure of brain regions that are critically involved in dysfunctional limbic-cortical network activity associated with major depressive disorder (MDD). Diffusion tensor imaging (DTI) and tract-based spatial statistics were used to investigate changes in white matter integrity in patients with MDD compared with healthy controls. A possible association between structural alterations in white matter tracts and DNA methylation of the SLC6A4 promoter region was also assessed...
2016: Translational Psychiatry
https://www.readbyqxmd.com/read/27439447/serotonin-transporter-gene-slc6a4-polymorphisms-are-associated-with-response-to-fluoxetine-in-south-indian-major-depressive-disorder-patients
#13
Aarthi Manoharan, Deepak Gopal Shewade, Ravi Philip Rajkumar, Surendiran Adithan
PURPOSE: Up to 30-40 % of the major depressive disorder patients do not respond sufficiently to antidepressant treatment. Genetic variations in the serotonin transporter gene have been implicated in modulating treatment response to selective serotonin reuptake inhibitors, and this association is influenced by ethnicity. We investigated the influence of serotonin transporter gene variants 5-HTTLPR and rs25531 in Indian population on fluoxetine response. METHODS: One hundred and two major depressive disorder patients were started on fluoxetine treatment and after 6 weeks, classified as responders (n = 56) and non-responders (n = 46) using Hamilton depression rating scale and genotyped...
October 2016: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/27023264/a-prospective-study-of-serotonin-and-norepinephrine-transporter-genes-and-the-response-to-desvenlafaxine-over-8-weeks-in-major-depressive-disorder
#14
C H Ng, C Bousman, D J Smith, N Dowling, K Byron, J King, J Sarris
No studies to date have evaluated SLC6A2 and SLC6A4 genetic polymorphisms influencing antidepressant response to desvenlafaxine. We conducted an 8-week, open-label, prospective pilot study in 35 patients with major depressive disorder to assess the effects of genetic variations in SLC6A2 and SLC6A4 on both efficacy and side effect profile of desvenlafaxine. Results revealed that homozygotes for the SLC6A4 HTTLPR S allele showed a 33% HDRS reduction compared to a 58% reduction for L allele carriers (p=0.037)...
September 2016: Pharmacopsychiatry
https://www.readbyqxmd.com/read/26974654/serotonin-and-dopamine-gene-variation-and-theory-of-mind-decoding-accuracy-in-major-depression-a-preliminary-investigation
#15
MULTICENTER STUDY
Arielle Y Zahavi, Mark A Sabbagh, Dustin Washburn, Raegan Mazurka, R Michael Bagby, John Strauss, James L Kennedy, Arun Ravindran, Kate L Harkness
Theory of mind-the ability to decode and reason about others' mental states-is a universal human skill and forms the basis of social cognition. Theory of mind accuracy is impaired in clinical conditions evidencing social impairment, including major depressive disorder. The current study is a preliminary investigation of the association of polymorphisms of the serotonin transporter (SLC6A4), dopamine transporter (DAT1), dopamine receptor D4 (DRD4), and catechol-O-methyl transferase (COMT) genes with theory of mind decoding in a sample of adults with major depression...
2016: PloS One
https://www.readbyqxmd.com/read/26746105/depression-as-a-risk-factor-for-alzheimer-s-disease-genes-steroids-cytokines-and-neurogenesis-what-do-we-need-to-know
#16
Joe Herbert, Paul J Lucassen
Depression (MDD) is prodromal to, and a component of, Alzheimer's disease (AD): it may also be a trigger for incipient AD. MDD is not a unitary disorder, so there may be particular subtypes of early life MDD that pose independent high risks for later AD, though the identification of these subtypes is problematical. There may either be a common pathological event underlying both MDD and AD, or MDD may sensitize the brain to a second event ('hit') that precipitates AD. MDD may also accelerate brain ageing, including altered DNA methylation, increased cortisol but decreasing DHEA and thus the risk for AD...
April 2016: Frontiers in Neuroendocrinology
https://www.readbyqxmd.com/read/26557993/no-association-of-bdnf-comt-maoa-slc6a3-and-slc6a4-genes-and-depressive-symptoms-in-a-sample-of-healthy-colombian-subjects
#17
Yeimy González-Giraldo, Andrés Camargo, Sandra López-León, Diego A Forero
Background. Major depressive disorder (MDD) is the second cause of years lived with disability around the world. A large number of studies have been carried out to identify genetic risk factors for MDD and related endophenotypes, mainly in populations of European and Asian descent, with conflicting results. The main aim of the current study was to analyze the possible association of five candidate genes and depressive symptoms in a Colombian sample of healthy subjects. Methods and Materials. The Spanish adaptation of the Hospital Anxiety and Depression Scale (HADS) was applied to one hundred eighty-eight healthy Colombian subjects...
2015: Depression Research and Treatment
https://www.readbyqxmd.com/read/26261165/association-of-serotonin-transporter-slc6a4-and-receptor-5htr1a-5htr2a-polymorphisms-with-response-to-treatment-with-escitalopram-in-patients-with-major-depressive-disorder-a-preliminary-study
#18
Aniruddha Basu, R K Chadda, Mamta Sood, Harpreet Kaur, Ritushree Kukreti
BACKGROUND & OBJECTIVES: Genetic factors have potential of predicting response to antidepressants in patients with major depressive disorder (MDD). In this study, an attempt was made to find an association between response to escitalopram in patients with MDD, and serotonin transporter (SLC6A4) and receptor (5HTR1A, 5HTR2A) polymorphisms. METHODS: Fifty five patients diagnosed as suffering from MDD, were selected for the study. The patients were treated with escitalopram over a period of 6-8 wk...
July 2015: Indian Journal of Medical Research
https://www.readbyqxmd.com/read/26175754/dna-methylation-and-single-nucleotide-variants-in-the-brain-derived-neurotrophic-factor-bdnf-and-oxytocin-receptor-oxtr-genes-are-associated-with-anxiety-depression-in-older-women
#19
Yvon C Chagnon, Olivier Potvin, Carol Hudon, Michel Préville
BACKGROUND: Environmental effects and personal experiences could be expressed in individuals through epigenetic non-structural changes such as DNA methylation. This methylation could up- regulate or down-regulate corresponding gene expressions and modify related phenotypes. DNA methylation increases with aging and could be related to the late expression of some forms of mental disease. The objective of this study was to evaluate the association between anxiety disorders and/or depression in older women and DNA methylation for four genes related to anxiety or depression...
2015: Frontiers in Genetics
https://www.readbyqxmd.com/read/26166439/genetic-polymorphisms-might-predict-suicide-attempts-in-mental-disorder-patients-a-systematic-review-and-meta-analysis
#20
REVIEW
Veronica de Medeiros Alves, Daniele Goncalves Bezerra, Tiago Gomes de Andrade, Valfrido Leao de Melo Neto, Antonio E Nardi
The aim of the present study was to analyze if the genetic polymorphisms might predict suicide attempts in mental disorder patients. The literature review and meta-analysis were conducted using the PubMed/Medline, Web of science and Scopus database using the terms: "5-HTT or SLC6A4 or 5-SERT and suicide, suicidal ideation or suicidal behavior or suicidal attempt". Thirty articles were analyzed. We found 17 articles that showed association and 13 articles that showed no association between LPR serotonin transporter polymorphism and suicide...
2015: CNS & Neurological Disorders Drug Targets
keyword
keyword
69533
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"